Sign up to access all valuation multiples
Middle East Pharmaceutical Industries Co is a holding company is engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments.
1998
541
LTM Revenue $105M
LTM EBITDA $28.5M
$693M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Middle East Pharma has a last 12-month revenue (LTM) of $105M and a last 12-month EBITDA of $28.5M.
In the most recent fiscal year, Middle East Pharma achieved revenue of $105M and an EBITDA of $27.5M.
Middle East Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Middle East Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $105M | XXX | $105M | XXX | XXX | XXX |
| Gross Profit | $64.8M | XXX | $64.9M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $28.5M | XXX | $27.5M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $24.3M | XXX | $25.2M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $21.3M | XXX | $21.3M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $11.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Middle East Pharma's stock price is SAR 128 (or $34).
Middle East Pharma has current market cap of SAR 2.6B (or $683M), and EV of SAR 2.6B (or $693M).
See Middle East Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $693M | $683M | XXX | XXX | XXX | XXX | $1.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Middle East Pharma has market cap of $683M and EV of $693M.
Middle East Pharma's trades at 6.6x EV/Revenue multiple, and 25.2x EV/EBITDA.
Equity research analysts estimate Middle East Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Middle East Pharma has a P/E ratio of 32.0x.
See valuation multiples for Middle East Pharma and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $683M | XXX | $683M | XXX | XXX | XXX |
| EV (current) | $693M | XXX | $693M | XXX | XXX | XXX |
| EV/Revenue | 6.6x | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBITDA | 24.3x | XXX | 25.2x | XXX | XXX | XXX |
| EV/EBIT | 28.6x | XXX | 27.5x | XXX | XXX | XXX |
| EV/Gross Profit | 10.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 32.0x | XXX | 32.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 181.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMiddle East Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Middle East Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Middle East Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Middle East Pharma and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Middle East Pharma acquired XXX companies to date.
Last acquisition by Middle East Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Middle East Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Middle East Pharma founded? | Middle East Pharma was founded in 1998. |
| Where is Middle East Pharma headquartered? | Middle East Pharma is headquartered in Saudi Arabia. |
| How many employees does Middle East Pharma have? | As of today, Middle East Pharma has 541 employees. |
| Who is the CEO of Middle East Pharma? | Middle East Pharma's CEO is Mr. Mohammed Maher Al-Ghannam. |
| Is Middle East Pharma publicy listed? | Yes, Middle East Pharma is a public company listed on SAU. |
| What is the stock symbol of Middle East Pharma? | Middle East Pharma trades under 4016 ticker. |
| When did Middle East Pharma go public? | Middle East Pharma went public in 2024. |
| Who are competitors of Middle East Pharma? | Similar companies to Middle East Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Middle East Pharma? | Middle East Pharma's current market cap is $683M |
| What is the current revenue of Middle East Pharma? | Middle East Pharma's last 12 months revenue is $105M. |
| What is the current EV/Revenue multiple of Middle East Pharma? | Current revenue multiple of Middle East Pharma is 6.6x. |
| Is Middle East Pharma profitable? | Yes, Middle East Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Middle East Pharma? | Middle East Pharma's last 12 months EBITDA is $28.5M. |
| What is Middle East Pharma's EBITDA margin? | Middle East Pharma's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Middle East Pharma? | Current EBITDA multiple of Middle East Pharma is 24.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
